Tumor News and Research

RSS

Researchers find gene mutations that may provide clues for treating AML patients

Although leukemia is one of the best studied cancers, the cause of some types is still poorly understood. Now, a newly found mutation in acute myeloid leukemia patients could account for half of the remaining cases of adult acute leukemia with an unknown origin.

19 Feb 2010

The Methodist Hospital Research Institute awarded $11.5M NIH grant for research into methods of targeting cancer stem cells

The Methodist Hospital Research Institute was awarded an $11.5 million Center Grant by the National Institutes for Health (NIH) today to study the best way to attack deadly cancer stem cells to enhance treatments for breast cancer. Other members of the team include Baylor College of Medicine and the University of Texas Health Science Center at Houston.

19 Feb 2010

Rituxan, intended for patients with CLL receives FDA approval

The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.

18 Feb 2010

Intezyne announces new patents covering IVECT Method in major pharmaceutical markets

Intezyne today announced the issuance of new patents that cover multiple dimensions of the Company’s revolutionary technology platform, the IVECTTM Method, in the major pharmaceutical markets of the United States, Europe, and Japan. All patents are wholly owned by Intezyne.

18 Feb 2010

Antigenics announces fourth-quarter and full-year 2009 financial results

Antigenics Inc. reported today its results for the quarter and year ended December 31, 2009. The company reported net income attributable to common stockholders of $1.7 million, or $0.02 per share, basic and diluted, for the fourth quarter of 2009, compared with net income attributable to common stockholders in the fourth quarter of 2008 of $3.9 million, or $0.06 per share, basic and diluted.

18 Feb 2010

NPG becomes official media partner to the 2010 WIN Symposium

Nature Publishing Group (NPG) is the official media partner to the 2010 WIN (Worldwide Innovative Networking) Symposium, it was announced today. The second annual WIN Symposium, which will be held in the Palais des Congrès, Paris, 7–9 July 2010, will bring together hundreds of oncology researchers from around the world to discuss how best to tailor therapies for patients with cancer.

18 Feb 2010

Nanotechnology plays a key role in detection and treatment of cancer

A world-renowned medical researcher discusses the key role that nanotechnology has begun to play in the detection and treatment of cancer in an article that will appear in the March 2010 edition of Mechanical Engineering magazine.

18 Feb 2010

Researchers discover new prognosis marker for prostate cancer

Measuring levels of the active form of the protein EGFR in the tumor and its vicinity can provide a more reliable prognosis for individuals with prostate cancer.

18 Feb 2010

Roche Molecular Systems, Merck Sharp & Dohme announce cancer therapeutics collaboration

Roche Molecular Systems, Inc. announced today a research collaboration with Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) providing Merck access to Roche's developmental microarray-based AmpliChip p53 Test, which is designed to detect mutations in the tumor suppressor gene p53. By identifying cancers that harbor a dysfunctional p53 gene, the companies aim to achieve better treatment outcomes in cancer patients by determining which patients are most likely to respond to certain investigational therapeutic candidates.

18 Feb 2010

World's smallest ultrasound device could offer a new level of home therapy for painful ailments

It looks more like an iPod than a medical tool. But the latest miniature ultrasound device created by Cornell biomedical engineering graduate student George K. Lewis could one day introduce a whole new level of home therapy for arthritis, injury and other painful ailments.

18 Feb 2010

Sorafenib drug therapy can reduce the size of primary kidney tumors before surgery

More than 57,000 Americans face a diagnosis of kidney cancer each year. Now patients with advanced disease may soon have another treatment option. Physicians who conducted a pilot study at UNC Lineberger Comprehensive Cancer Center found that therapy before surgery with the drug sorafenib can reduce the size of large tumors and could be safely undertaken administered without adding significantly to the risks of surgery.

17 Feb 2010

Researchers discover new strategy to overcome drug resistance in breast cancer

Combining tamoxifen, the world's most prescribed breast cancer agent, with a compound found in the flowering plant feverfew may prevent initial or future resistance to the drug, say researchers at Georgetown Lombardi Comprehensive Cancer Center.

17 Feb 2010

Researchers use new strategy to develop cancer vaccines

Researchers at National Jewish Health and the University of Colorado School of Medicine have used a new strategy to develop cancer vaccines that are remarkably effective in mice. In the February 16 issue of the Proceedings of the National Academy of Sciences, Kimberly Jordan, PhD, Jill Slansky, PhD, and John Kappler, PhD, report that 100 percent of the mice vaccinated with a peptide they developed remained alive and tumor-free for at least 60 days after inoculation with colon cancer cells.

17 Feb 2010

Research assesses the overall efficacy of palliative chest RT in patients with advanced NSCLC

Research published in the February edition of the Journal of Thoracic Oncology sought to assess the overall efficacy of split-course palliative chest radiotherapy (RT) for symptom relief in patients with advanced non-small cell lung cancer. Additionally, researchers investigated the impact the regimen's two-week break has on survival outcomes.

17 Feb 2010

Calypso real-time tumor tracking system usage during IMRT for prostate cancer reduces rectal/urinary side effects

Calypso Medical Technologies, Inc., a developer of targeting technology used for accurate, precise real-time tracking of tumor targets, today announced the online publication of a clinical study in Urology (The GOLD JOURNAL). The prospective, multi-site study, entitled, “Assessing the Impact of Margin Reduction (AIM),” is the first outcomes-based study to evaluate the quality of life of high-dose intensity-modulated radiotherapy (IMRT) to the prostate with tightly contoured treatment technically described as “reduced treatment margins.”

17 Feb 2010

New fluorescent probes improve tumor detection in mice

Building on his Nobel Prize-winning work creating fluorescent proteins that light up the inner workings of cells, a team of researchers led by Howard Hughes Medical Institute investigator Roger Tsien, PhD, professor of pharmacology, chemistry and biochemistry at the University of California, San Diego and the Moores UCSD Cancer Center has developed biological probes that can stick to and light up tumors in mice.

17 Feb 2010

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, EPOGEN and PROCRIT ESAs

Amgen Inc. and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa).

17 Feb 2010

EntreMed's ENMD-2076 for AML receives FDA's orphan drug designation

EntreMed, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AML).

16 Feb 2010

Researchers identify potential therapeutic targets for treatment of neuroblastoma

A team of researchers, led by Patrick Mehlen, at Universit- de Lyon, France, has identified the protein NT-3 and the cell-surface molecule to which it binds (TrkC) as potential therapeutic targets for the treatment of neuroblastoma - the most frequent solid tumor in young children- by studying human neuroblastoma cells in vitro and after xenotransplantation into mice and chicks.

15 Feb 2010

Research findings may open door to new therapeutic strategies for serious health problems

Drugs that target the way cells convert nutrients into energy could offer new approaches to treating a range of conditions including heart attack and stroke. Using a new way to screen for potential drugs, a team led by Massachusetts General Hospital (MGH) researchers has identified several FDA-approved agents, including an over-the-counter anti-nausea drug, that can shift cellular energy metabolism processes in animals.

15 Feb 2010

Tumor News and Research

Researchers find gene mutations that may provide clues for treating AML patients

The Methodist Hospital Research Institute awarded $11.5M NIH grant for research into methods of targeting cancer stem cells

Rituxan, intended for patients with CLL receives FDA approval

Intezyne announces new patents covering IVECT Method in major pharmaceutical markets

Antigenics announces fourth-quarter and full-year 2009 financial results

NPG becomes official media partner to the 2010 WIN Symposium

Nanotechnology plays a key role in detection and treatment of cancer

Researchers discover new prognosis marker for prostate cancer

Roche Molecular Systems, Merck Sharp & Dohme announce cancer therapeutics collaboration

World's smallest ultrasound device could offer a new level of home therapy for painful ailments

Sorafenib drug therapy can reduce the size of primary kidney tumors before surgery

Researchers discover new strategy to overcome drug resistance in breast cancer

Researchers use new strategy to develop cancer vaccines

Research assesses the overall efficacy of palliative chest RT in patients with advanced NSCLC

Calypso real-time tumor tracking system usage during IMRT for prostate cancer reduces rectal/urinary side effects

New fluorescent probes improve tumor detection in mice

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, EPOGEN and PROCRIT ESAs

EntreMed's ENMD-2076 for AML receives FDA's orphan drug designation

Researchers identify potential therapeutic targets for treatment of neuroblastoma

Research findings may open door to new therapeutic strategies for serious health problems

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News